PDF

Int J Med Sci 2023; 20(3):415-428. doi:10.7150/ijms.79516 This issue Cite

Research Paper

Bioinformatics-based analysis of the roles of sex hormone receptors in endometriosis development

Xiaoling Zhao¹, Weimin Kong¹ , Chunxiao Zhou², Boer Deng^1,2, He Zhang¹, Huimin Guo¹, Shuning Chen¹, Zhendong Pan¹

1. Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China.
2. Division of Gynecologic Oncology and Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

✉ Corresponding author: Weimin Kong. E-mail address: kwm1967edu.cn

Abstract

Endometriosis is a hormone-dependent disease in women of reproductive age and seriously affects women's health. To analyze the involvement of sex hormone receptors in endometriosis development, we performed bioinformatics analysis using four datasets derived from the Gene Expression Omnibus (GEO) database, which may help us understand the mechanisms by which the sex hormones act in vivo in endometriosis patients. The enrichment analysis and protein-protein interaction (PPI) analysis of the differentially expressed genes (DEGs) revealed that there are different key genes and pathways involved in eutopic endometrium aberrations of endometriosis patients and endometriotic lesions, and sex hormone receptors, including androgen receptor (AR), progesterone receptor (PGR) and estrogen receptor 1 (ESR1), may play important roles in endometriosis development. Androgen receptor (AR), as the hub gene of endometrial aberrations in endometriotic patients, showed positive expression in the main cell types for endometriosis development, and its decreased expression in the endometrium of endometriotic patients was also confirmed by immunohistochemistry (IHC). The nomogram model established based on it displayed good predictive value.

Keywords: Endometriosis, Hormone receptor, Bioinformatics analysis

Introduction

Endometriosis is caused by the presence of endometrium-like tissues outside of the uterus [1]. It is estimated that endometriosis can affect 10-15% of reproductive-age women, resulting in pelvic pain and infertility [1, 2]. The long-term presence of endometriosis also carries the risk of cancers [3, 4]. Several hypotheses, such as retrograde menstruation theory, have been proposed to explain the etiology and pathogenesis of endometriosis, however, none of them can fully explain it.

It is now basically clear that endometriosis is a hormone-dependent inflammatory disease [5]. In the endometrium of patients with endometriosis, estrogen, which can promote endometrial cell proliferation and inflammation, was dominant while progesterone was resistant and failed to properly antagonize the effects of estrogen [5, 6]. The progesterone resistance and estrogen dominance in ectopic lesions lead to increased lesion growth and contribute to pelvic pain and infertility [5, 6]. Androgen, which can reduce the chronic pain and inflammation, can be converted to estrogen by aromatase in the eutopic and ectopic endometrium of women with endometriosis, thereby increasing local estrogen levels [7]. So far, the exact mechanisms by which these hormones act in vivo remain unclear, making prevention and treatment challenging.

Currently, with the rapid development of sequencing technology and the emergence of bioinformatics analysis and public databases, we can obtain a massive amount of gene information to explore the underlying molecular mechanisms of the disease [8]. The sex hormones mediate the biological effects on endometrium by binding to their receptors, occurring at cell surface and in the nucleus [5, 9]. Understanding the roles of these receptors in the pathogenesis of endometriosis may help us uncover the mechanisms of these sex hormones' actions. Therefore, in this study, we aimed to investigate the roles of sex hormone receptors in endometriosis development by bioinformatics analysis, which may provide us with new insights into the disease. The workflow of this study was presented in Figure 1.

Methods

Data collection and DEGs identification

The gene expression profiles associated with endometriosis were obtained from the GEO database, which is searched using 'endometriosis' and 'endometrioma' as keywords and restricts the source of tissues to 'homo sapiens'. The information of the selected datasets is displayed in Table 1. Then the datasets (GSE51981, GSE120103, GSE37837 and GSE7305) with complete clinical information and sufficient case numbers were selected for further analysis. GSE51981, based on the GPL570 platform, includes 34 normal endometria and 77 endometria from endometriosis patients [10]. GSE120103, based on GPL6480, includes 18 normal endometria and 18 endometria from endometriosis patients [11]. The datasets GSE37837 and GSE7305 were produced using the GPL6480 and GPL570 platforms, which contained 36 samples (18 ectopic lesions and 18 matched control endometria from the same patients) and 20 samples (10 ectopic lesions and 10 matched control endometria from the same patients), respectively [12, 13].

 Figure 1 

Flowchart of the integrated analysis for endometriosis. AR, androgen receptor; ESR1, estrogen receptor 1; ESR2, estrogen receptor 2; GPER1, G-protein coupled estrogen receptor 1; PGR, progesterone receptor; PGRMC1, progesterone receptor membrane component 1; PGRMC2, progesterone receptor membrane component 2; GEO, Gene Expression Omnibus; DEGs, the differentially expressed genes; PPI, protein-protein interaction.

The DEGs were identified using GEO2R, an interactive tool that can compare two or more groups of samples with the limma package [14]. After normalization and log2 transformation, the genes with a fold change >1 and a P value <0.05 were selected.

Enrichment analysis

Enrichment analyses were performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) (https://david.ncifcrf.gov) [15]. Biological processes (BP) were selected for further analysis to identify the biological attributes of the DEGs. A P value <0.05 was set as the cutoff for statistical significance.

PPI network analysis

To explore the interactions among the identified DEGs, we mapped them to the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database (https://cn.string-db.org) to assess the protein-protein interaction information ^[16]. To ensure reliable interactions, only experiments were selected as the active interaction sources, with the minimum required interaction scores at 0.150. The other indicated network properties consist of organism (Homo sapiens); network type (full string network); and meaning of network edges (evidence). Then, Cytoscape software was used to visualize the PPI network ^[16]. CytoHubba, a plug-in of Cytoscape software, was used to rank nodes and screen the hub genes [17]. The top 10 genes calculated by topological algorithms were considered hub genes.

The analysis of androgen receptor (AR) using the Human Protein Atlas (HPA) database

HPA (https://www.proteinatlas.org/) is a comprehensive database covering the protein expression of many cancerous and normal tissues, with millions of images for human tissue samples included [18, 19]. The expression level of AR in human normal tissues was evaluated in the HPA database and presented as a histogram. The single-cell profiles of the endometrium are also pictured in the HPA database, and the expression level of AR in each cell type is presented.

AR expression and location detection

Endometrial tissues and ectopic lesions were collected from patients with indications for hysterectomy in Beijing Obstetrics and Gynecology Hospital from January 2018 to December 2021. Normal endometria, including 3 postmenopausal endometria and 6 premenopausal endometria were collected from patients with grade III cervical intraepithelial neoplasia or stage IA1 cervical cancer. Ectopic lesions and matched eutopic endometrial samples were collected from 6 patients with endometriosis combined with grade III cervical intraepithelial neoplasia or cervical cancer stage IA1. All the patients had normal menstrual cycles and didn't receive any hormone therapy. This study was approved by the Ethics Committee of Beijing Obstetrics and Gynecology Hospital affiliated with Capital Medical University, and written informed consent was obtained from all patients.

Immunohistochemistry (IHC) was used to detect AR expression using an AR antibody (#DF6783, Affinity, Japan) at a dilution of 1:200. The H-score (H-score = [1*(% of cells 1+) + 2*(% of cells 2+) + 3*(% of cells 3+)], where 1 = weak expression, 2 = moderate expression, and 3 = strong expression) was applied to quantify the IHC images [20]. Immunofluorescent (IF) staining was performed to determine the location of AR in the cells using an AR antibody (#DF6783, Affinity, Japan) at a dilution of 1:100.

Identification of proteins that interact with hormone receptors

The interactors of hormone receptors were identified from two databases: GPS-Prot (http://www.gpsprot.org) and Biogrid (https://thebiogrid.org). GPS-Prot is a web-based visualization platform for PPIs that allows new user-generated data to be uploaded [21]. Biogrid is a biomedical interaction repository with data compiled through comprehensive curation efforts [22]. The differentially expressed interactors of AR between eutopic endometria and normal endometria with a fold change >1 and a P value <0.05 were selected for the establishment of the models.

Diagnostic model establishment

A nomogram was established using the rms package in R software with GSE51981 as the training set [23]. Genes included in the diagnostic model analysis were selected by least absolute shrinkage and selection operator (LASSO) regression using the glmnet package [24]. Then, GSE120103, containing 36 samples, was used as the test set to verify the model. The receiver operating characteristic (ROC) curve calculated by the pROC package was used to test the efficacy of the diagnostic model [23].

Results

Identification of differentially expressed genes (DEGs) and sex hormone receptors expression

In the present study, a total of 6073 and 6633 DEGs between normal endometria and those of patients with endometriosis were identified in GSE120103 and GSE51981, respectively. 1787 DEGs were obtained from their intersection. Among them, the numbers of up-regulated genes and down-regulated genes in both two datasets were 359 and 459, respectively. A total of 2455 and 1835 DEGs between eutopic and ectopic endometrial tissues of the same patients from GSE37837 and GSE7305, respectively, were also selected. A total of 384 DEGs were found after intersection, comprising 134 up-regulated genes and 220 down-regulated genes in both two datasets. The genes were listed in Supplementary Table S1.

Then the expression of sex hormone receptors in eutopic and ectopic endometria was analyzed in GSE51981, GSE120103, GSE7305 and GSE37837 (Figure 2A-G). In the eutopic endometria of endometriosis patients, AR, progesterone receptor (PGR) and progesterone receptor membrane component 1 (PGRMC1) showed decreased expression compared with normal endometria, with log₂FC<1 in both the GSE51981 and GSE120103 datasets. In the ectopic endometria of endometriotic patients, only ESR1, one of the estrogen receptors, showed markedly decreased expression in both the GSE7305 and GSE37837 datasets, with log₂FC<1.

Enrichment analysis of the DEGs

To identify the biological functions of the DEGs in the development of endometriosis, enrichment analyses were conducted using DAVID, and the top 20 enriched biological processes were represented in Table 2-3. The DEGs between eutopic endometrium and normal endometrium mainly enriched in 'positive regulation of macromolecule metabolic process', 'positive regulation of metabolic process' and 'positive regulation of macromolecule biosynthetic process'. And the up-regulated genes in eutopic endometrium were mainly enriched in 'cell activation', 'anatomical structure development' and 'leukocyte activation' while the down-regulated genes were mainly enriched in 'chromosome organization', 'cellular component organization or biogenesis' and 'organelle organization'. For the DEGs between ectopic endometrium and eutopic endometrium, the genes were primarily enriched in 'anatomical structure morphogenesis', 'anatomical structure development' and 'single-multicellular organism process'. Moreover, the up-regulated genes in ectopic endometrium were significantly enriched in 'regulation of response to stimulus', 'regulation of multicellular organismal process' and 'positive regulation of response to stimulus', while the down-regulated genes were significantly enriched in 'regulation of cell cycle', 'cell cycle' and 'cell cycle process'.

 Figure 2 

The expression of sex hormone receptors in the datasets. (A-G) The expression of sex hormone receptors, including AR (A), ESR1 (B), ESR2 (C), GPER1 (D), PGR (E), PGRMC1 (F) and PGRMC2 (G), in the datasets. AR, androgen receptor; ESR1, estrogen receptor 1; ESR2, estrogen receptor 2; GPER1, G-protein coupled estrogen receptor 1; PGR, progesterone receptor; PGRMC1, progesterone receptor membrane component 1; PGRMC2, progesterone receptor membrane component 2. FC of GSE51981 and GSE120103= the value of endometria from endometriosis patients/ the value of normal endometria; FC of GSE37837 and GSE7305= the value of ectopic endometria from the same patients/the value of eutopic endometria from endometriosis patients. FC, fold change.

Considering that endometriosis is a hormone-dependent gynecological disease, we screened the hormone-related biological processes. For eutopic endometrium derived from endometriotic patients and normal endometrium, the processes, including 'response to hormone', 'cellular response to hormone stimulus', 'response to steroid hormone', 'cellular response to peptide hormone stimulus', 'response to peptide hormone' and 'cellular response to steroid hormone stimulus', were screened. Both AR and PGR were involved in the biological processes named 'response to hormone', 'cellular response to hormone stimulus', 'response to steroid hormone' and 'cellular response to steroid hormone stimulus' (Table 4). For ectopic endometrium and eutopic endometrium of endometriotic patients, the biological processes, including 'cellular response to luteinizing hormone stimulus', 'response to luteinizing hormone', 'hormone catabolic process', 'response to peptide hormone', 'response to hormone', 'response to growth hormone', 'cellular response to peptide hormone stimulus' and 'hormone metabolic process', were screened. ESR1 involved in 'response to hormone' and 'hormone metabolic process' (Table 5).

In addition, we screened the biological processes in which sex hormone receptors were involved. The top 20 enriched biological processes were listed in Table 6. AR and PGR were involved in most of the processes in which the DEGs between eutopic endometrium and normal endometrium were significantly enriched. 'Positive regulation of macromolecule metabolic process', 'positive regulation of metabolic process' and 'positive regulation of macromolecule biosynthetic process' were the top 3 enriched processes in which both AR and PGR were involved. Only 15 significantly enriched biological processes in which PGRMC1 was involved. 'Single-organism cellular process', 'single-organism process' and 'cellular biosynthetic process' ranked top 3. ESR1 was also involved in almost all the enriched processes of the DEGs between ectopic endometrium and eutopic endometrium, and 'anatomical structure morphogenesis', 'anatomical structure development' and 'single-multicellular organism process' ranked the top 3.

PPI network analysis of the DEGs

To investigate the associations among the screened DEGs, PPI networks were constructed using Cytoscape software. And then the top 10 genes were selected from each method using CytoHubba. The network of the DEGs between normal endometrium and those of patients with endometriosis contained 683 nodes and 5105 edges, with AR, PGR and PGRMC1 involved in the network construction (Figure 3A). AR interacts with 9 up-regulated genes (KDM6B, SRC, FGR, NR4A1, FOS, CEBPB, TNK2, ZBTB16 and KAT5) and 25 down-regulated genes (NCOA4, SPOP, CTNNB1, SMARCA4, HSP90AB1, NCOR1, HSPA5, TCF4, HSP90AA1, KPNA3, TXNDC5, SMARCC1, DEPDC1, NUP107, APPL1, PIK3R1, ATRX, MAPK1, KDM4A, RAH, KDM5B, BECN1, KPNB1 and MYLIP) directly. PGR interacts with 3 up-regulated genes (KDM6B, SRC and NR4A1) and 6 down-regulated genes (MAPK1, NUP107, HSP90AA1, NCOR1, HSP90AB1 and SPOP) directly. PGRMC1 interacts with 1 up-regulated gene (HSD11B1L) and 5 down-regulated genes (PTPLAD1, MPRIP, HNRNPH, CANX and SRSI3) directly. Besides, the hub genes of the DEGs between eutopic endometrium of endometriosis patients and normal endometrium were calculated and displayed in Supplementary Table S2. Both AR and PGR were identified as the hub genes.

The network of the DEGs between ectopic endometrium and eutopic endometrium contained 213 nodes and 571 edges (Figure 3B). ESR1 interacts with 5 up-regulated genes (FHK2, ST13, CAV1, JUNB and EPAS1) and 8 down-regulated genes (SOX9, WHSC1, AURKA, XBP1, SMC2, MAP3K1, RAD51 and ZMYNDB) directly. What's more, ESR1 was also identified as one of the hub genes (Supplementary Table S2).

The potential roles of AR in endometriosis development

The roles of estrogen and progesterone in endometriosis development and the relevance of their receptors to endometriosis have been discussed and validated in many studies [5, 6]. Considering the lack of research on AR in endometriosis, we next explored the expression of AR in human tissues and cells to explore the possibility of AR involvement in the formation of endometriosis.

The expression of AR in normal human tissues was detected at both RNA and protein levels (Figure 4A-B). The results showed that the RNA expression of AR can be detected in all tissues except bone marrow, while its protein expression was found only in kidney, testis, epididymis, seminal vesicle, fallopian tube, endometrium, cervix and breast. What's more, AR is expressed in all cell types of endometria, with the greatest expression in endometrial stromal cells (Figure 4C-D). The expression of AR in endometrium tissues was also detected in this study using the IHC method (Figure 5A-E). We found that AR expression is retained in the post-menopausal endometrium and positive AR staining can be detected in both endometrial epithelial cells and stromal cells using the IHC method. The expression level of AR in normal premenopausal endometria was significantly higher than that in endometria derived from endometriotic patients (P<0.05). No significant difference in AR expression was found between eutopic endometria and their matched ectopic lesions.

Endometrial stromal cells are the main cell type expressing AR in endometrial tissues, and they are also an important cell type for endometriosis development [25]. So, we examined the location of AR in endometrial stromal cells using the IF method. The results showed that AR localizes to the cytosol and nucleus (Figure 5F).

Considering the role of AR in the endometrial aberrations of endometriosis patients, we identified 94 interactors of AR using GPS-Prot and Biogrid. Then, AR and its interactors, including 95 proteins, were further screened by LASSO regression analysis. Seven genes, namely, APPL1, CSNK2A1, ERG, KDM4A, SMARCC1, SUZ12 and TRIM25, were selected to establish the diagnostic model for endometriosis, and a nomogram was constructed based on them (Figure 6A-C). To test the diagnostic efficacy of the nomogram, the ROC curves of the training set GSE51981 and test set GSE120103 were plotted, yielding an AUC of 0.984 for the training set and an AUC of 0.948 for the test set (Figure 6D-E).

Discussion

Estrogen, progesterone and androgen are well-known hormones that play important roles in female reproductive disease [6, 26-29]. The effects of estrogen can be mediated by three types of receptors, including ESR1, estrogen receptor 2 (ESR2) and G-protein coupled estrogen receptor 1 (GPER1/GPR30) [30, 31]. Progesterone exerts its biological effects by binding to progesterone receptors, including the nuclear receptor PGR and membrane receptors PGRMC1 and progesterone receptor membrane component 2 (PGRMC2) [32]. Upon binding to an androgen, AR can translocate into the cell nucleus and then activate the transcription of its target genes [33].

 Figure 3 

PPI network analysis of the DEGs. In the network, the red circles represent up-regulated genes, while the blue circles represent down-regulated genes. The size of the circle is positively correlated with |Log₂FC|. (A) PPI network analysis of the DEGs between normal endometria and those of endometriosis patients. (B) PPI network analysis of the DEGs between eutopic endometria and ectopic endometria from the same patients. PPI, protein‑protein interaction.

 Figure 4 

The expression of AR in human tissues obtained from HPA database. (A) The RNA expression level of AR in human tissues. (B) The protein expression level of AR in human tissues. (C-D) The single-cell profile of human endometrium (C) and AR expression in each cell type (D). AR, androgen receptor; HPA, the Human Protein Atlas.

 Figure 5 

The expression of AR in human endometrial tissues. (A-D) Representative images of AR staining in postmenopausal endometrium (A), premenopausal endometrium (B), eutopic endometrium from endometriotic patients (C) and their matched ectopic lesion (D). (E) The corresponding histograms of positive AR staining level in different groups. (F) Representative images of AR staining in endometrial stromal cells. Scale bar 100 µm. AR, androgen receptor.

 Figure 6 

Establishment of a diagnostic model for endometriosis. (A) LASSO coefficient profiles of the genes in the normal endometrium and eutopic endometrium tissue from endometriosis patients. (B) Selection of the optimal parameter (lambda) in the LASSO model for the normal endometrium and eutopic endometrium tissue from endometriosis patients. (C) A nomogram model established based on the LASSO results. (D) ROC curve of the diagnostic nomogram model for the training set (GSE51981). (E) ROC curve of the diagnostic nomogram model for GSE120103. LASSO, least absolute shrinkage and selection operator; ROC curve, receiver operating characteristic curve.

Previous studies have reported that the decreased ESR1/ESR2 in ectopic lesions leads to the decreased expression of PGR, which can exacerbate the inflammatory response, thereby contributing to endometriosis. In our study, we found that, compared with eutopic endometria, the expression of ESR1 in ectopic lesions was decreased. However, no significant changes in PGR and ESR2 were discovered. The most widely accepted hypothesis for the occurrence of endometriosis is Sampson's retrograde menstruation theory, which postulates that it is retrograde menstruation, which enters the cavity, that results in endometriosis [34]. The phenomenon that the prevalence of retrograde menstruation is more than 90% while endometriosis affects only 10% of the female population further reflects that there remain different characteristics between normal endometria and the eutopic endometria of endometriosis patients [34, 35]. So, in this study, we also analyzed the expression of the receptors between eutopic endometria of endometriotic patients and normal endometria of healthy women. The results showed that, compared with normal endometria, the expression of AR, PGR, and PGRMC1 in eutopic endometria derived from patients with endometriosis was decreased. Of course, strictly speaking, PGRMC1 doesn't belong to the steroid receptors [36]. As a member of a multi-protein progesterone-binding complex, PGRMC1 cannot bind directly to progesterone [36].

Next, the enrichment and PPI analysis were performed. The results showed that the DEGs involved in the eutopic endometrium aberrations of endometriotic patients and ectopic lesions functioned differently. However, both contained genes that participate in the hormone response, in which the nuclear receptors (AR, PGR and ESR1) were included. These nuclear receptors (AR, PGR and ESR1) were also involved in almost all the top 20 enriched biological processes of the DEGs. What's more, both AR and PGR were identified as the hub genes between normal endometria and those of endometriosis patients, and ESR1 was selected as the hub gene between eutopic and ectopic endometria from the same patients. These results imply that sex steroid hormones and their receptors may play important roles in endometriosis development. Besides steroid hormone response, we found that peptide-related processes were also involved in endometriosis development. The synthesis of sex steroid hormones begins with the secretion of gonadotropin-releasing hormone (GnRH), which belongs to peptide hormones [37]. In addition, luteinizing hormone (LH), which can stimulate the production of sex hormones, also contributes to the formation of ectopic lesions. Both 'cellular response to luteinizing hormone stimulus' and 'response to luteinizing hormone' were enriched.

Several studies have previously reported the aberrations of estrogen and progesterone receptor pathways in endometriosis [6, 31, 38, 39]. As for AR, it is reported that the positive staining of AR can be detected in the stroma and glandular epithelium of eutopic endometrium and ectopic lesions [40], and cytosine, adenine, and guanine (CAG) repeat variants of AR gene were associated with the increased risk of endometriosis [41, 42]. However, the aberrations of AR expression in eutopic and ectopic endometrium was uncertain [40]. In this study, the IHC results displayed the significantly decreased expression of AR in the eutopic endometrium of endometriotic patients compared with normal endometrium. This study also found a high expression level of AR in the organs of the male and female reproductive systems, such as testis, endometrium and breast. And the positive expression of AR in the main cell types for endometriosis development can also be detected, especially in endometrial stromal cells. However, no significant difference was found between ectopic lesions and their matched eutopic tissues, although the expression of AR in ectopic lesions seemed to be higher. For postmenopausal endometrium, AR expression seemed to be decreased, however, a significant difference has not been detected, possibly due to the limited sample numbers.

Then we performed disease prediction using AR and its interactors. Seven independent factors, including APPL1, CSNK2A1, ERG, KDM4A, SMARCC1, SUZ12 and TRIM25, were filtered. The results showed that the AUC of the nomogram model for the training set (GSE51981) was 0.984; this finding was further verified on the test set (GS120103), with an AUC of 0.948. APPL1 may function as an adaptor protein in many pathways, including the insulin and adiponectin signaling pathways, and suppresses androgen receptor transactivation by potentiating Akt activity [43, 44]. APPL1, Akt, and AR form a complex in which Akt serves as the bridge factor for the association of APPL with AR [43]. CSNK2A1 is the gene encoding CK2 alpha, the catalytic subunit of protein kinase casein kinase 2 (CK2) [45]. CK2 can increase AR protein stability and promote AR-dependent transcriptional activity [45]. Additionally, a significant positive correlation was observed between CSNK2A1 and AR mRNA levels in prostate cancer [46]. ERG is a member of the E-26 transformation-specific (ETS) family, which has been extensively studied in the field of prostate cancer in recent years [47]. ERG can disrupt AR signaling by inhibiting AR expression or by binding to AR at gene-specific loci and inhibiting its activity [48]. KDM4A is a histone demethylase related to AR [49]. KDM4A can enhance AR-activated gene transcription by forming complexes with ligand-bound AR, thereby mediating multiple processes, including cell proliferation, differentiation, development, and metabolism [50]. SMARCC1 is a core subunit of the SWI/SNF complex and has been found to play important roles in the development of several cancers [51, 52]. The SWI/SNF complex, containing 5 core subunits and 7-15 accessory subunits, functions by interfering with histone-DNA contacts [53]. Almost 25% of all cancers harbor mutations in one or more of these subunits [54]. The interaction of SMARCC1 and AR has been shown by affinity capture-MS and affinity capture-western experimental techniques [55, 56]. SUZ12 is the core subunit of polycomb repressive complex 2 (PRC2), the epigenetic repressor complex [57]. It was reported that PRC2 can regulate the AR-associated signaling pathway [58]. The expression of SUZ12 was also correlated with the transcriptional function of AR [59]. TRIM25 has been defined as the downstream target of ESR1 and has been shown by affinity capture-MS to interact with AR [59, 60]. Although we identified the gene sets that appear to have predictive value for endometriosis development, their use for clinical prediction still needs substantial clinical validation. Instead, the gene sets that can modulate AR signaling were involved in endometriosis development and displayed good predictive value, which also indicates the importance of AR signaling on disease occurrence and provides new targets for the disease. Androgen can inhibit endometrial growth, reduce the chronic pain and inflammation [7, 61, 62]. The administration of the synthetic androgen Danazol is effective in treating pain and reducing lesions in endometriosis, but its significant androgenic side-effects limit its use [61]. The search for the specific targets of AR signaling regulation in endometriosis may provide the new insight for the development of treatment options. Of course, the further research on the roles of AR in endometriosis development and how these genes influence AR signaling in endometriosis still needs to be further explored.

In summary, this study explored the importance of sex hormone receptors in endometriosis development and improved our understandings of the pathogenesis of endometriosis. Furthermore, the potential roles of AR in endometriosis development provide us new insights into the disease, which may lead to the development of novel treatment strategies.

Supplementary Material

Supplementary tables.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Grant no. 81871142). Additionally, we thank the personnel of the Gene Expression Omnibus (GEO) database for providing their platforms and contributors for uploading their meaningful datasets.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Osuchowska-Grochowska I, Blicharska E, Gogacz M. et al. Brief Review of Endometriosis and the Role of Trace Elements. Int J Mol Sci. 2021 22

2. Fukunaga M. Uterus-like mass in the uterine cervix: superficial cervical endometriosis with florid smooth muscle metaplasia?. Virchows Arch. 2001;438:302-5

3. Murakami K, Kotani Y, Nakai H. et al. Endometriosis-Associated Ovarian Cancer: The Origin and Targeted Therapy. Cancers (Basel). 2020 12

4. Kralickova M, Lagana AS, Ghezzi F. et al. Endometriosis and risk of ovarian cancer: what do we know?. Arch Gynecol Obstet. 2020;301:1-10

5. Saunders PTK, Horne AW. Endometriosis: Etiology, pathobiology, and therapeutic prospects. Cell. 2021;184:2807-24

6. Marquardt RM, Kim TH, Shin JH. et al. Progesterone and Estrogen Signaling in the Endometrium: What Goes Wrong in Endometriosis?. Int J Mol Sci. 2019 20

7. Franca PRC, Lontra ACP, Fernandes PD. Endometriosis: A Disease with Few Direct Treatment Options. Molecules. 2022 27

8. Wu J, Fang X, Xia X. Identification of Key Genes and Pathways associated with Endometriosis by Weighted Gene Co-expression Network Analysis. Int J Med Sci. 2021;18:3425-36

9. Yilmaz BD, Bulun SE. Endometriosis and nuclear receptors. Hum Reprod Update. 2019;25:473-85

10. Tamaresis JS, Irwin JC, Goldfien GA. et al. Molecular classification of endometriosis and disease stage using high-dimensional genomic data. Endocrinology. 2014;155:4986-99

11. Bhat MA, Sharma JB, Roy KK. et al. Genomic evidence of Y chromosome microchimerism in the endometrium during endometriosis and in cases of infertility. Reprod Biol Endocrinol. 2019;17:22

12. Khan MA, Sengupta J, Mittal S. et al. Genome-wide expressions in autologous eutopic and ectopic endometrium of fertile women with endometriosis. Reprod Biol Endocrinol. 2012;10:84

13. Hever A, Roth RB, Hevezi P. et al. Human endometriosis is associated with plasma cells and overexpression of B lymphocyte stimulator. Proc Natl Acad Sci U S A. 2007;104:12451-6

14. Barrett T, Wilhite SE, Ledoux P. et al. NCBI GEO: archive for functional genomics data sets-update. Nucleic Acids Res. 2013;41:D991-5

15. Dennis G Jr, Sherman BT. et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4:P3

16. Shannon P, Markiel A, Ozier O. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498-504

17. Chin CH, Chen SH, Wu HH. et al. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11

18. Uhlen M, Fagerberg L, Hallstrom BM. et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419

19. Uhlen M, Oksvold P, Fagerberg L. et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 2010;28:1248-50

20. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995;48:876-8

21. Fahey ME, Bennett MJ, Mahon C. et al. GPS-Prot: a web-based visualization platform for integrating host-pathogen interaction data. BMC Bioinformatics. 2011;12:298

22. Oughtred R, Stark C, Breitkreutz BJ. et al. The BioGRID interaction database: 2019 update. Nucleic Acids Res. 2019;47:D529-D41

23. Balachandran VP, Gonen M, Smith JJ. et al. Nomograms in oncology: more than meets the eye. The Lancet Oncology. 2015;16:e173-e80

24. Waldmann P, Ferencakovic M, Meszaros G. et al. AUTALASSO: an automatic adaptive LASSO for genome-wide prediction. BMC Bioinformatics. 2019;20:167

25. Bulun SE, Yilmaz BD, Sison C. et al. Endometriosis. Endocr Rev. 2019;40:1048-79

26. Falcone T, Flyckt R. Clinical Management of Endometriosis. Obstet Gynecol. 2018;131:557-71

27. Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev. 2013;34:130-62

28. Gompel A. Progesterone and endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2020;69:95-107

29. Berger MH, Messore M, Pastuszak AW. et al. Association Between Infertility and Sexual Dysfunction in Men and Women. Sex Med Rev. 2016;4:353-65

30. Eyster KM. The Estrogen Receptors: An Overview from Different Perspectives. Methods Mol Biol. 2016;1366:1-10

31. Chantalat E, Valera MC, Vaysse C. et al. Estrogen Receptors and Endometriosis. Int J Mol Sci. 2020 21

32. Grimm SL, Hartig SM, Edwards DP. Progesterone Receptor Signaling Mechanisms. J Mol Biol. 2016;428:3831-49

33. Matsumoto T, Shiina H, Kawano H. et al. Androgen receptor functions in male and female physiology. J Steroid Biochem Mol Biol. 2008;109:236-41

34. Koninckx PR, Ussia A, Adamyan L. et al. Pathogenesis of endometriosis: the genetic/epigenetic theory. Fertil Steril. 2019;111:327-40

35. Alnafakh R, Choi F, Bradfield A. et al. Endometriosis Is Associated with a Significant Increase in hTERC and Altered Telomere/Telomerase Associated Genes in the Eutopic Endometrium, an Ex-Vivo and In Silico Study. Biomedicines. 2020 8

36. Rohe HJ, Ahmed IS, Twist KE. et al. PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharmacol Ther. 2009;121:14-9

37. Lovejoy DA. Peptide hormone evolution: functional heterogeneity within GnRH and CRF families. Biochem Cell Biol. 1996;74:1-7

38. Tang ZR, Zhang R, Lian ZX. et al. Estrogen-Receptor Expression and Function in Female Reproductive Disease. Cells. 2019 8

39. Reis FM, Coutinho LM, Vannuccini S. et al. Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. Hum Reprod Update. 2020;26:565-85

40. Carneiro MM, Morsch DM, Camargos AF. et al. Androgen receptor and 5alpha-reductase are expressed in pelvic endometriosis. BJOG. 2008;115:113-7

41. Fujimoto J, Hirose R, Sakaguchi H. et al. Expression of size-polymorphic androgen receptor (AR) gene in ovarian endometriosis according to the number of cytosine, adenine, and guanine (CAG) repeats in AR alleles. Steroids. 1999;64:526-9

42. Shin JJ, Choi YM, Choi HY. et al. Androgen receptor cytosine, adenine, and guanine trinucleotide repeat polymorphism in Korean patients with endometriosis: A case-control study. Eur J Obstet Gynecol Reprod Biol. 2017;218:1-4

43. Yang L, Lin HK, Altuwaijri S. et al. APPL suppresses androgen receptor transactivation via potentiating Akt activity. J Biol Chem. 2003;278:16820-7

44. Artimani T, Najafi R. APPL1 as an important regulator of insulin and adiponectin-signaling pathways in the PCOS: A narrative review. Cell Biol Int. 2020;44:1577-87

45. Borgo C, D'Amore C, Sarno S. et al. Protein kinase CK2: a potential therapeutic target for diverse human diseases. Signal Transduct Target Ther. 2021;6:183

46. Trembley JH, Kren BT, Abedin MJ. et al. CK2 Pro-Survival Role in Prostate Cancer Is Mediated via Maintenance and Promotion of Androgen Receptor and NFkappaB p65 Expression. Pharmaceuticals (Basel). 2019 12

47. Adamo P, Ladomery MR. The oncogene ERG: a key factor in prostate cancer. Oncogene. 2016;35:403-14

48. Yu J, Yu J, Mani RS. et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell. 2010;17:443-54

49. Morozov VM, Li Y, Clowers MM. et al. Inhibitor of H3K27 demethylase JMJD3/UTX GSK-J4 is a potential therapeutic option for castration resistant prostate cancer. Oncotarget. 2017;8:62131-42

50. Shin S, Janknecht R. Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. Biochem Biophys Res Commun. 2007;359:742-6

51. Cai X, Zhou J, Deng J. et al. Prognostic biomarker SMARCC1 and its association with immune infiltrates in hepatocellular carcinoma. Cancer Cell Int. 2021;21:701

52. Xiao ZM, Lv DJ, Yu YZ. et al. SMARCC1 Suppresses Tumor Progression by Inhibiting the PI3K/AKT Signaling Pathway in Prostate Cancer. Front Cell Dev Biol. 2021;9:678967

53. Carmel-Gross I, Levy E, Armon L. et al. Human Pluripotent Stem Cell Fate Regulation by SMARCB1. Stem Cell Reports. 2020;15:1037-46

54. Mittal P, Roberts CWM. The SWI/SNF complex in cancer - biology, biomarkers and therapy. Nat Rev Clin Oncol. 2020;17:435-48

55. Wang Q, Udayakumar TS, Vasaitis TS. et al. Mechanistic relationship between androgen receptor polyglutamine tract truncation and androgen-dependent transcriptional hyperactivity in prostate cancer cells. J Biol Chem. 2004;279:17319-28

56. Lempiainen JK, Niskanen EA, Vuoti KM. et al. Agonist-specific Protein Interactomes of Glucocorticoid and Androgen Receptor as Revealed by Proximity Mapping. Mol Cell Proteomics. 2017;16:1462-74

57. Long Y, Hwang T, Gooding AR. et al. RNA is essential for PRC2 chromatin occupancy and function in human pluripotent stem cells. Nat Genet. 2020;52:931-8

58. Liu Q, Wang G, Li Q. et al. Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer. Int J Cancer. 2019;145:415-26

59. Chuang CH, Wang WJ, Li CF. et al. The combination of the prodrugs perforin-CEBPD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer. Cell Death Dis. 2014;5:e1220

60. Vatapalli R, Sagar V, Rodriguez Y. et al. Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer. Nat Commun. 2020;11:4153

61. Vannuccini S, Clemenza S, Rossi M. et al. Hormonal treatments for endometriosis: The endocrine background. Rev Endocr Metab Disord. 2022;23:333-55

62. Simitsidellis I, Saunders PTK, Gibson DA. Androgens and endometrium: New insights and new targets. Mol Cell Endocrinol. 2018;465:48-60

Author contact

Corresponding author: Weimin Kong. E-mail address: kwm1967edu.cn

Received 2022-10-4
Accepted 2023-1-20
Published 2023-2-5

Citation styles

©2024 Ivyspring International Publisher. Terms of use